Posterior vitreous detachment following intravitreal drug injection.

Abstract

BACKGROUND:

To evaluate the incidence of posterior vitreous detachment (PVD) induced by intravitreal injection of different intravitreal drugs.

METHODS:

This prospective observational study included 61 patients (61 eyes) with different underlying retinal diseases: exudative age-related macular degeneration (n = 47), cystoid macular edema (CME) after retinal vein occlusion (n = 8), and CME of other origin (n = 6). Bevazicumab (1.25 mg) was injected into 25 eyes, ranibizumab (0.5 mg) into 27 eyes, triamcinolone (4 mg) into six eyes, and a combination of bevacizumab and triamcinolone into three eyes. Patients with initial PVD were excluded. Patients were followed for at least 4-6 weeks after their last injection by Fourier-domain OCT, fundus biomicroscopy and ultrasound B-examination.

RESULTS:

Overall, 15 of 61 eyes developed a PVD after intravitreal injection (n = 6 after ranibizumab, n = 7 after bevacizumab and n = 2 after triamcinolon) within a mean follow-up period of 11.1 weeks. PVD occurred in three eyes after the first injection, in three eyes after the second, and in seven eyes after the third injection. Incidence of PVD correlated with increasing age.

CONCLUSION:

Intravitreal injection of commonly-used drugs seems to induce posterior vitreous detachment, which may thus influence the outcome of the underlying disease.

• Authors: Ulrich Geck, Nicole Pustolla, Husnia Baraki, Abed Atili, Nicolas Feltgen, Hans Hoerauf
• Journal: Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie (Graefes Arch Clin Exp Ophthalmol) Vol. 251 Issue 7 Pg. 1691-5 (Jul 2013) ISSN: 1435-702X [Electronic] Germany
• PMID: 23381655 (Publication Type: Journal Article)

Chemical References

• Angiogenesis Inhibitors
• Antibodies, Monoclonal, Humanized
• Bevacizumab
• Triamcinolone Acetonide
• Ranibizumab

Topics

• Adult
• Aged
• Aged, 80 and over
• Angiogenesis Inhibitors (administration & dosage, therapeutic use)
• Antibodies, Monoclonal, Humanized (administration & dosage, therapeutic use)
• Bevacizumab
• Female
• Follow-Up Studies
• Fourier Analysis
• Humans
• Incidence
• Intravitreal Injections (adverse effects)
• Macular Edema (drug therapy)
• Male
• Microscopy, Acoustic
• Middle Aged
• Prospective Studies
• Ranibizumab
• Retinal Vein Occlusion (drug therapy)
• Tomography, Optical Coherence
• Treatment Outcome
• Triamcinolone Acetonide (administration & dosage, therapeutic use)
• Vitreous Detachment (diagnosis, etiology)
• Wet Macular Degeneration (drug therapy)